InvestSMART

Clarity Pharmaceuticals Ltd (ASX: CU6) - Announcements

Current share price for CU6 : $2.180 0.08 (3.81%)+

ASX company news and announcements for Clarity Pharmaceuticals Ltd (CU6) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clarity Pharmaceuticals Ltd (CU6) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clarity Pharmaceuticals Ltd (CU6), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clarity Pharmaceuticals Ltd (CU6)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$813 Clarity expands supply of Cu-64 for Phase III trials 14 Jun 2023 8:51AM $0.780 $2.180 risen by 179.49%
$813 Presentation at Jefferies Healthcare Conference 13 Jun 2023 9:04AM $0.770 $2.180 risen by 183.12%
$813 Recruitment complete for Phase II prostate cancer trial 7 Jun 2023 8:27AM $0.750 $2.180 risen by 190.67%
$813 Clarity to present at ASCO and SNMMI 2023 Annual Meetings 26 May 2023 1:23PM $0.715 $2.180 risen by 204.90%
$813 Notification regarding unquoted securities - CU6 25 May 2023 3:23PM $0.750 $2.180 risen by 190.67%
$813 Theranostic prostate cancer trial advances to cohort 2 24 May 2023 9:52AM $0.680 $2.180 risen by 220.59%
$813 Final Director's Interest Notice - O'Bryan Tear 16 May 2023 10:07AM $0.700 $2.180 risen by 211.43%
$813 Initial Director's Interest Notice 2 May 2023 5:04PM $0.760 $2.180 risen by 186.84%
$813 Quarterly Activities/Appendix 4C Cash Flow Report 28 Apr 2023 1:36PM $0.740 $2.180 risen by 194.59%
$813 Clarity Receives $6.7 million R&D Tax Incentive Refund 18 Apr 2023 12:41PM $0.745 $2.180 risen by 192.62%
$813 Notification of cessation of securities - CU6 11 Apr 2023 5:27PM $0.720 $2.180 risen by 202.78%
$813 Notification regarding unquoted securities - CU6 5 Apr 2023 12:07PM $0.680 $2.180 risen by 220.59%
$813 Clarity update on NorthStar copper-67 production 4 Apr 2023 9:59AM $0.720 $2.180 risen by 202.78%
$813 Cleansing Notice 28 Mar 2023 3:00PM $0.760 $2.180 risen by 186.84%
$813 Application for quotation of securities - CU6 28 Mar 2023 9:16AM $0.750 $2.180 risen by 190.67%
$813 Clarity Corporate Presentation 13 Mar 2023 12:55PM $0.875 $2.180 risen by 149.14%
$813 Clarity confirms no supply interruptions 2 Mar 2023 3:29PM $0.910 $2.180 risen by 139.56%
$813 World leading expert in copper-67 joins Clarity SAB 1 Mar 2023 11:06AM $0.860 $2.180 risen by 153.49%
$813 Half Yearly Report and Accounts 28 Feb 2023 4:44PM $0.880 $2.180 risen by 147.73%
$813 Appendix 4D 28 Feb 2023 4:16PM $0.880 $2.180 risen by 147.73%
$813 Change of Director's Interest Notice - Biggin 21 Feb 2023 2:13PM $0.815 $2.180 risen by 167.48%
$813 Cleansing Notice 21 Feb 2023 10:52AM $0.810 $2.180 risen by 169.14%
$813 Notification regarding unquoted securities - CU6 21 Feb 2023 10:46AM $0.810 $2.180 risen by 169.14%
$813 Application for quotation of securities - CU6 21 Feb 2023 10:45AM $0.810 $2.180 risen by 169.14%
$813 50% recruitment milestone for NET diagnostic Phase II trial 16 Feb 2023 9:07AM $0.830 $2.180 risen by 162.65%

351 - 375 of 511 results

Page 15 of 21

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.